Products for Research Use Only

CGP60474

CAT: 0804-HY-11009-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-11009-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively) . CGP60474 is a selective and ATP-competitive PKC inhibitor[1][2][3].
CAS Number
164658-13-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CDK; PKC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CGP60474.html
Purity
98.90
Solubility
DMSO : ≥ 50 mg/mL
Smiles
ClC1=CC(NC2=NC=CC(C3=CC=NC(NCCCO)=C3)=N2)=CC=C1
Molecular Formula
C18H18ClN5O
Molecular Weight
355.82
Precautions
H302, H315, H319, H335
References & Citations
[1]Jorda R, et al. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?. J Med Chem. 2018;61 (20) :9105-9120.|[2]Han HW, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent anti-endotoxemic agent. Sci Rep. 2018;8 (1) :14969. Published 2018 Oct 8.|[3]Stanetty P, et al. Novel and efficient access to phenylamino-pyrimidine type protein kinase C inhibitors utilizing a Negishi cross-coupling strategy. J Org Chem. 2005;70 (13) :5215-5220.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK4; CDK5; CDK7; CDK9; PKC

Popular Products